Press Releases April 30, 2026 05:00 PM

Kinross announces Annual Shareholder Meeting voting results

Kinross Gold Corporation announces outcomes of its 2026 Annual Shareholder Meeting including Board of Directors election and key resolutions.

By Hana Yamamoto
Share
Twitter Reddit Facebook LinkedIn
KGC

Kinross Gold Corporation held its 2026 Annual Shareholder Meeting, successfully electing all nominated Board members with strong shareholder support. Key voting results include overwhelming approval of the "Say on Pay" executive compensation resolution and appointment of auditors. These results reflect shareholder confidence in the company’s governance and strategic direction.

Kinross announces Annual Shareholder Meeting voting results
KGC
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • All Board of Directors nominees were elected with over 96% shareholder approval, indicating strong supporter confidence.
  • The "Say on Pay" resolution on executive compensation received over 92% votes in favor, suggesting broad satisfaction with leadership remuneration.
  • Appointment of auditors was approved with over 90% support, maintaining audit continuity and corporate oversight.
  • The meeting's outcomes impact the mining sector, particularly gold mining, and influence investor sentiment in the resource extraction industry.

TORONTO, April 30, 2026 (GLOBE NEWSWIRE) -- Kinross Gold Corporation (TSX: K, NYSE: KGC) has announced the detailed voting results of the election of its Board of Directors, which took place at the Company’s Annual Meeting of Shareholders on April 30, 2026.

The nominees listed in the Management Information Circular dated March 3, 2026, were elected as directors of Kinross at the meeting (see detailed voting results below).

Board of Directors voting results

NomineeVotes for% forVotes withheld% withheldGeorge V. Albino873,748,05398.53%13,012,4871.47%Glenn A. Ives878,492,17399.07%8,268,3670.93%Ave G. Lethbridge855,129,09196.43%31,631,4493.57%Michael A. Lewis868,555,17697.95%18,205,3642.05%Candace J. MacGibbon885,840,02599.90%920,5150.10%Elizabeth D. McGregor885,938,27199.91%822,2690.09%Kelly J. Osborne875,425,76498.72%11,334,7771.28%George N. Paspalas874,226,42498.59%12,534,1171.41%J. Paul Rollinson885,970,33699.91%790,2040.09%David A. Scott879,626,04599.20%7,134,4960.80%


Voting results on the other items of business at the Annual Meeting of Shareholders are as follows:

“Say on Pay” resolution on executive compensation

Votes for% forVotes against% against824,534,05392.98%62,226,4837.02%


Appointment of auditors

Votes for% forVotes withheld% withheld849,889,85890.49%89,334,3649.51%


A report on all matters voted on at the meeting has been filed on SEDAR+.

About Kinross Gold Corporation

Kinross is a Canadian-based global senior gold mining company with operations and projects in the United States, Brazil, Mauritania, Chile and Canada. Our focus is on delivering value based on the core principles of responsible mining, operational excellence, disciplined growth, and balance sheet strength. Kinross maintains listings on the Toronto Stock Exchange (symbol: K) and the New York Stock Exchange (symbol: KGC).

Media Contact
Samantha Sheffield
Director, Corporate Communications
phone: 416-365-3034
Samantha.Sheffield@Kinross.com

Investor Relations Contact
David Shaver                                 
Executive Vice-President, Investor Relations & Communications                
phone: 416-365-2854                        
InvestorRelations@Kinross.com

Source: Kinross Gold Corporation


Risks

  • Despite strong voting results, market volatility or changing gold prices could impact future company performance, affecting shareholder value.
  • Operational risks tied to Kinross's geographic diversification include regulatory, environmental, and political uncertainties in countries like the U.S., Brazil, Mauritania, Chile, and Canada.
  • Executive compensation approval might prompt scrutiny if company performance declines, affecting governance perceptions and stock valuation.

More from Press Releases

Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026 Jun 14, 2026 Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026) Jun 14, 2026 Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Jun 14, 2026